A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Intravenous Doses of IGN002 Administered Weekly to Subjects With Refractory Non-Hodgkin Lymphoma (NHL)
Phase of Trial: Phase I
Latest Information Update: 10 Jan 2018
At a glance
- Drugs IGN 002 (Primary)
- Indications Non-Hodgkin's lymphoma
- Focus Adverse reactions; First in man
- Sponsors ImmunGene
- 07 Jun 2016 Trial design presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
- 08 Jan 2016 According to Valor Biotherapeutics media release,the first patient was dosed in this study in January 2016.
- 18 Dec 2015 Planned End Date changed from 1 Sep 2018 to 1 Dec 2018, according to ClinicalTrials.gov record.